Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
Evaxion Biotech A/S (NASDAQ: EVAX) has reported strong validation of its AI-Immunology™ platform in multiple clinical trials. The company, specializing in AI-powered vaccine development, has gathered evidence from three separate clinical trials demonstrating the platform's ability to select clinically relevant vaccine targets.
Key findings include:
- Statistically significant correlation between AI-Immunology™ prediction scores and immunological responses in patients
- Strongest outcomes generated by top-ranked AI-Immunology™ vaccine targets
- In one trial, a statistically significant correlation between AI-Immunology™ prediction scores and Progression Free Survival (PFS)
The data supports the platform's potential in selecting effective vaccine targets and allows for continuous refinement of AI-Immunology™, broadening its commercial potential. Evaxion's CEO, Christian Kanstrup, emphasized the importance of generating relevant clinical data for the ongoing development of the platform.
Evaxion Biotech A/S (NASDAQ: EVAX) ha riportato una forte validazione della sua piattaforma AI-Immunology™ in molteplici trial clinici. L'azienda, specializzata nello sviluppo di vaccini potenziati dall'IA, ha raccolto prove da tre diversi trial clinici che dimostrano la capacità della piattaforma di selezionare bersagli vaccinali clinicamente rilevanti.
I risultati principali includono:
- Correlazione statisticamente significativa tra i punteggi delle previsioni AI-Immunology™ e le risposte immunologiche nei pazienti
- I risultati migliori generati dai bersagli vaccinali AI-Immunology™ di maggior rango
- In un trial, una correlazione statisticamente significativa tra i punteggi delle previsioni AI-Immunology™ e la Sopravvivenza Libera da Progressione (PFS)
I dati supportano il potenziale della piattaforma nella selezione di bersagli vaccinali efficaci e consentono un continuo affinamento dell'AI-Immunology™, ampliando il suo potenziale commerciale. Il CEO di Evaxion, Christian Kanstrup, ha sottolineato l'importanza di generare dati clinici rilevanti per lo sviluppo continuo della piattaforma.
Evaxion Biotech A/S (NASDAQ: EVAX) ha informado sobre una fuerte validación de su plataforma AI-Immunology™ en múltiples ensayos clínicos. La empresa, especializada en el desarrollo de vacunas impulsadas por inteligencia artificial, ha reunido evidencia de tres ensayos clínicos distintos que demostrar la capacidad de la plataforma para seleccionar objetivos de vacuna clínicamente relevantes.
Los hallazgos clave incluyen:
- Correlación estadísticamente significativa entre los puntajes de predicción de AI-Immunology™ y las respuestas inmunológicas en los pacientes
- Los resultados más robustos generados por los objetivos de vacuna AI-Immunology™ mejor clasificados
- En un ensayo, una correlación estadísticamente significativa entre los puntajes de predicción de AI-Immunology™ y la Supervivencia Libre de Progresión (PFS)
Los datos respaldan el potencial de la plataforma para seleccionar objetivos de vacuna eficaces y permiten un continuo refinamiento de AI-Immunology™, ampliando su potencial comercial. El CEO de Evaxion, Christian Kanstrup, enfatizó la importancia de generar datos clínicos relevantes para el desarrollo continuo de la plataforma.
Evaxion Biotech A/S (NASDAQ: EVAX)는 여러 임상 시험에서 AI-Immunology™ 플랫폼의 강력한 검증을 보고했습니다. AI 기반 백신 개발에 특화된 이 회사는 플랫폼이 임상적으로 관련 있는 백신 대상을 선택하는 능력을 입증하는 세 가지 별도의 임상 시험에서 증거를 수집했습니다.
주요 발견으로는:
- AI-Immunology™ 예측 점수와 환자의 면역 반응 간의 통계적으로 유의미한 상관관계
- 상위 순위의 AI-Immunology™ 백신 대상으로 생성된 가장 우수한 결과들
- 한 시험에서 AI-Immunology™ 예측 점수와 무진행 생존율(PFS) 간의 통계적으로 유의미한 상관관계
이 데이터는 효과적인 백신 대상을 선택하는 플랫폼의 잠재력을 지지하며 AI-Immunology™의 지속적인 개선을 가능하게 하여 상업적 잠재력을 넓힙니다. Evaxion의 CEO인 Christian Kanstrup은 플랫폼의 지속적인 개발을 위한 관련 임상 데이터 생성의 중요성을 강조했습니다.
Evaxion Biotech A/S (NASDAQ: EVAX) a rapporté une forte validation de sa plateforme AI-Immunology™ dans plusieurs essais cliniques. La société, spécialisée dans le développement de vaccins alimentés par l'IA, a recueilli des preuves de trois essais cliniques distincts démontrant la capacité de la plateforme à sélectionner des cibles vaccinales cliniquement pertinentes.
Les principaux résultats incluent :
- Corrélation statistiquement significative entre les scores de prédiction de AI-Immunology™ et les réponses immunologiques chez les patients
- Les meilleurs résultats générés par les cibles vaccinales AI-Immunology™ les mieux classées
- Dans un essai, une corrélation statistiquement significative entre les scores de prédiction de AI-Immunology™ et la Survie Sans Progression (PFS)
Les données soutiennent le potentiel de la plateforme à sélectionner des cibles vaccinales efficaces et permettent un raffinement continu de AI-Immunology™, élargissant ainsi son potentiel commercial. Le CEO d'Evaxion, Christian Kanstrup, a souligné l'importance de générer des données cliniques pertinentes pour le développement continu de la plateforme.
Evaxion Biotech A/S (NASDAQ: EVAX) hat eine starke Validierung seiner AI-Immunologie™-Plattform in mehreren klinischen Studien gemeldet. Das Unternehmen, das sich auf die Entwicklung von Impfstoffen mit KI spezialisiert hat, hat aus drei separaten klinischen Studien Beweise gesammelt, die die Fähigkeit der Plattform zur Auswahl klinisch relevanter Impfstoffziele zeigen.
Wichtige Erkenntnisse umfassen:
- Statistisch signifikante Korrelation zwischen den Vorhersagepunkten der AI-Immunologie™ und den immunologischen Reaktionen bei Patienten
- Die besten Ergebnisse wurden durch hochrangige AI-Immunologie™-Impfstoffziele erzielt
- In einer Studie eine statistisch signifikante Korrelation zwischen den Vorhersagepunkten der AI-Immunologie™ und dem Progressionsfreien Überleben (PFS)
Die Daten unterstützen das Potenzial der Plattform bei der Auswahl effektiver Impfstoffziele und ermöglichen eine kontinuierliche Verfeinerung der AI-Immunologie™, wodurch ihr kommerzielles Potenzial erweitert wird. Der CEO von Evaxion, Christian Kanstrup, betonte die Bedeutung der Erzeugung relevanter klinischer Daten für die kontinuierliche Entwicklung der Plattform.
- Strong validation of AI-Immunology™ platform in multiple clinical trials
- Statistically significant correlation between AI prediction scores and immunological responses
- Correlation between AI prediction scores and Progression Free Survival in one trial
- Ongoing clinical data generation allows for continuous refinement of the AI platform
- Broadening commercial potential of the AI-Immunology™ platform
- None.
Insights
The clinical validation of Evaxion's AI-Immunology™ platform across three separate trials is a significant development in personalized cancer vaccine research. The platform's ability to predict effective vaccine targets (neoantigens) with a high degree of accuracy, as evidenced by the statistically significant correlations between AI prediction scores and patient immune responses, is particularly noteworthy.
Key points of impact:
- Strong correlation between AI-predicted targets and actual immune responses in patients
- Statistically significant link between prediction scores and Progression Free Survival in one trial
- Validation across multiple clinical trials (EVX-01, EVX-02 and EVX-03)
- Potential for continuous refinement of the AI platform through ongoing data generation
This validation could accelerate the development of more effective personalized cancer vaccines, potentially improving treatment outcomes for cancer patients. However, it's important to note that while these results are promising, larger phase 2 and 3 trials will be necessary to fully establish the clinical efficacy and safety of this approach.
From an investor's perspective, this news is potentially significant for Evaxion Biotech (NASDAQ: EVAX). The validation of their AI-Immunology™ platform across multiple clinical trials strengthens the company's technological moat and could lead to increased interest from potential partners or acquirers in the pharmaceutical industry.
Key financial implications:
- Potential for accelerated development timelines, reducing R&D costs
- Increased likelihood of successful clinical outcomes, possibly leading to higher valuation
- Enhanced competitive position in the personalized cancer vaccine market
- Possibility of licensing opportunities or partnerships with larger pharmaceutical companies
However, investors should be cautious as Evaxion is still a clinical-stage company with no approved products. The market cap of
- Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets
- Strongest outcomes are generated by the top-ranked AI-Immunology™ vaccine targets, thereby linking AI-vaccine design with real-world evidence
- This underscores the platform’s unique potential in selecting effective vaccine targets
- The ongoing generation of relevant clinical data allows for continuous refinement of AI-Immunology™ thereby broadening the commercial potential of the platform
COPENHAGEN, Denmark, October 9, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has now evidence from three different clinical trials validating the vaccine target predictions of its AI platform.
Evaxion has developed three personalized cancer vaccine candidates with the use of its AI-Immunology™ platform. Two of these – EVX-01 and EVX-02 – have completed clinical phase 1 testing and EVX-01 is currently in phase 2, while the third – EVX-03 – is an IND-ready vaccine candidate.
The AI-Immunology™ platform identifies cancer vaccine targets, so called neoantigens, and assigns a prediction score reflecting the likelihood of each vaccine target to elicit a specific immune response against the tumor. In all three clinical trials, a statistically significant correlation was observed between the AI-Immunology™ prediction scores and the immunological responses measured in the patients, with the most robust responses being generated by vaccine targets with the highest AI-Immunology™ prediction scores.
Further, in the one trial where it was assessed, a statistically significant correlation was demonstrated between AI-Immunology™ prediction scores and Progression Free Survival (PFS) in patients, underscoring the platform's ability to identify vaccine targets with meaningful clinical impact.
“We are proud to have collected such strong clinical data documenting the unique predictive capabilities of the AI-Immunology™ platform across several clinical trials. The correlation between the platform’s prediction score and clinical outcome is unique and provides very solid guidance for the further development of personalized cancer vaccines based upon AI-Immunology™. Generating highly relevant clinical data is very important for our ability to apply constant learning loops, allowing for the continuous development of AI-Immunology™,” says Christian Kanstrup, CEO of Evaxion.
About AI-Immunology™
AI-Immunology™ is a scalable and adaptable artificial intelligence technology platform at the forefront of vaccine discovery for infectious diseases and cancers. By integrating the collective power of proprietary AI models PIONEER™, EDEN™, RAVEN™, and ObsERV™, the platform can model the complexity of the patient’s immune system. AI-Immunology™ advanced computational modeling swiftly and uniquely identifies, predicts, and designs vaccine candidates, revolutionizing the landscape of immunotherapy by offering a holistic and personalized approach to combat fast-evolving pathogens and malignant cells.
Contact information
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion-biotech.com
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide ongoing COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia and the Middle East; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
What clinical trials has Evaxion Biotech (EVAX) conducted for its AI-Immunology™ platform?
How does Evaxion's AI-Immunology™ platform select cancer vaccine targets?
What significant correlations were observed in Evaxion's (EVAX) clinical trials?
How does the clinical data benefit the development of Evaxion's (EVAX) AI-Immunology™ platform?
